Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : New Roche data at 2021 AAN -2-

04/08/2021 | 01:00am EDT
                          Fluid (Atrophied T2 Lesion Volume) 
                          in Primary-Progressive Multiple 
                          Sclerosis: Results from the Phase 
                          III ORATORIO Study 
-----------------------  ----------------------------------------------  ------------------------------- 
                         Recently Diagnosed Early-Stage                  P15.099 
                          RRMS: NEDA, ARR, Disability Progression,        P15: MS Clinical Trials 
                          Serum Neurofilament and Safety:                 and Therapeutics 
                          1-Year Interim Data from the Ocrelizumab 
                          Phase IIIb ENSEMBLE Study 
                         ----------------------------------------------  ------------------------------- 
                         Adherence and Persistence to Disease-modifying  P15.228 
                          Therapies for Multiple Sclerosis                P15: MS Health Care 
                          and Their Impact on Clinical and                System/Policy Based 
                          Economic Outcomes in a U.S. Claims              Research 
                          Database 
                         ----------------------------------------------  ------------------------------- 
                         Safety of Ocrelizumab in Multiple               P15.203 
                          Sclerosis: Updated Analysis in                  P15: MS Therapeutics 
                          Patients with Relapsing and Primary             MOA and Safety 
                          Progressive Multiple Sclerosis 
-----------------------  ----------------------------------------------  ------------------------------- 
Fenebrutinib             The Safety of Fenebrutinib in a                 S25.005 (oral presentation) 
 for Multiple             Large Population of Patients with               S25: MS and CNS Inflammatory 
 Sclerosis                Diverse Autoimmune Indications                  Disease: Emerging Therapeutics 
                          Supports Investigation in Multiple              and Biomarkers 
                          Sclerosis (MS)                                  Tuesday, April 20 at 
                                                                          4:40 pm ET 
-----------------------  ----------------------------------------------  ------------------------------- 
                         Fenebrutinib Demonstrates the Highest           P15.091 
                          Potency of Bruton Tyrosine Kinase               P15: MS Clinical Trials 
                          Inhibitors (BTKis) in Phase 3 Clinical          and Therapeutics 
                          Development for Multiple Sclerosis 
                          (MS) 
-----------------------  ----------------------------------------------  ------------------------------- 
ENSPRYNG (satralizumab)  Satralizumab in Patients with Neuromyelitis     P2.019 
 for Neuromyelitis        Optica Spectrum Disorder and Concomitant        P2: Autoimmune Neurology: 
 Optica Spectrum          Autoimmune Disease                              Advances in Neuromyelitis 
 Disorder                                                                 Optica Spectrum Disorder 
                                                                          (NMOSD) 
-----------------------  ----------------------------------------------  ------------------------------- 
Neuromyelitis            Disease Phenotype Correlates with               P2.091 
 Optica Spectrum          Treatment Change in NMOSD Patients              P2: Autoimmune Neurology: 
 Disorder                 of the CIRCLES Cohort                           Clinical Observations 
                                                                          and Advances 
-----------------------  ----------------------------------------------  ------------------------------- 
                         Demographic and Relapse Correlates              P2.013 
                          of Treatment Change in NMOSD Patients:          P2: Autoimmune Neurology: 
                          Analysis of the CIRCLES Study                   Advances in Neuromyelitis 
                                                                          Optica Spectrum Disorder 
                                                                          (NMOSD) 
-----------------------  ----------------------------------------------  ------------------------------- 
                         Relapse Profile Correlates with                 P2.012 
                          Treatment Change in NMOSD Patients              P2: Autoimmune Neurology: 
                          of the CIRCLES Cohort                           Advances in Neuromyelitis 
                                                                          Optica Spectrum Disorder 
                                                                          (NMOSD) 
                         ----------------------------------------------  ------------------------------- 
                         Correlates of Rituximab Discontinuation         P2.014 
                          in Patients with NMOSD: a CIRCLES               P2: Autoimmune Neurology: 
                          Cohort Analysis                                 Advances in Neuromyelitis 
                                                                          Optica Spectrum Disorder 
                                                                          (NMOSD) 
-----------------------  ----------------------------------------------  ------------------------------- 
Alzheimer's              Linking Amyloid to Cognition in                 P1.052 
 Disease                  the Pathogenesis and Treatment                  P1: Aging and Dementia: 
                          of Alzheimer's Disease: Toward                  Biomarkers 
                          the Development of a "Quantitative 
                          A/T/N Model" 
-----------------------  ----------------------------------------------  ------------------------------- 
Gantenerumab             Utilization of Home Nursing to                  P1.014 
 for Alzheimer's          Mitigate the Impact of COVID-19                 P1: Aging and Dementia: 
 Disease                  on the Conduct of the Gantenerumab              Clinical Trials 
                          GRADUATE Trials 
-----------------------  ----------------------------------------------  ------------------------------- 
Semorinemab              A Disease Progression Model for                 P1.061 
 for Alzheimer's          Alzheimer's Disease Predicts Longitudinal       P1: Aging and Dementia: 
 Disease                  Trajectory of CDR-SB Score Across               Neuropsychology 
                          Different Stages of the Disease 
-----------------------  ----------------------------------------------  ------------------------------- 
Huntington's             Burden of Illness among U.S. Medicare           P14.043 
 Disease                  Beneficiaries with Late-onset Huntington's      P14: Huntington's Disease 
                          Disease 
-----------------------  ----------------------------------------------  ------------------------------- 
                         Clinical Characteristics of Late-Onset          P14.046 
                          Huntington's Disease in North Americans         P14: Huntington's Disease 
                          from the Enroll-HD Study 
-----------------------  ----------------------------------------------  ------------------------------- 
                         Clustering and Prediction of Disease            P14.147 
                          Progression Trajectories in Huntington's        P14: Clinical Trials, 
                          Disease: An Analysis of the Enroll-HD           Surveys, and Studies 
                          and REGISTRY Database Using a Machine           in Movement Disorders 
                          Learning Approach 
-----------------------  ----------------------------------------------  ------------------------------- 
 
   About EVRYSDI(TM) (risdiplam) 
 
   EVRYSDI is a survival of motor neuron 2 (SMN2) splicing modifier 
designed to treat SMA by increasing production of the survival of motor 
neuron (SMN) protein. SMN protein is found throughout the body and is 
critical for maintaining healthy motor neurons and movement. EVRYSDI is 
administered daily at home in liquid form by mouth or by feeding tube. 
 
 
 
   The U.S. Food and Drug Administration (FDA) approved EVRYSDI for the 
treatment of SMA in adults and children 2 months of age and older. 
EVRYSDI was granted PRIME designation by the European Medicines Agency 
(EMA) in 2018 and Orphan Drug Designation by FDA and EMA in 2017 and 
2019, respectively. At this time, EVRYSDI has been approved in 38 
countries and submitted in a further 33 countries. 
 
 
 
   About OCREVUS(R) (ocrelizumab) 
 
   OCREVUS is the first and only therapy approved for both RMS (including 
clinically isolated syndrome, RRMS and active, or relapsing, SPMS) and 
PPMS, with dosing every six months. OCREVUS is a humanised monoclonal 
antibody designed to target CD20-positive B cells, a specific type of 
immune cell thought to be a key contributor to myelin (nerve cell 
insulation and support) and axonal (nerve cell) damage. This nerve cell 
damage can lead to disability in people with MS. Based on preclinical 
studies, OCREVUS binds to CD20 cell surface proteins expressed on 
certain B cells, but not on stem cells or plasma cells, suggesting that 
important functions of the immune system may be preserved. 
 
 
 
   OCREVUS is administered by intravenous infusion every six months. The 
initial dose is given as two 300 mg infusions given two weeks apart. 
Subsequent doses are given as single 600 mg infusions. With rapidly 
growing real-world experience and more than 200,000 people treated 
globally, OCREVUS is the first and only therapy approved for relapsing 
MS (RMS; including RRMS and active, or relapsing, secondary progressive 

(MORE TO FOLLOW) Dow Jones Newswires

April 08, 2021 01:00 ET (05:00 GMT)

All news about ROCHE HOLDING AG
01:21pROCHE  :  FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection ..
BU
11:57aNovartis, Genentech Get FDA OK of Self-Administered Xolair
DJ
09:12aROCHE  : U.S. lab products provider Avantor to buy Germany's Ritter for $1.1 bln
RE
06:11aREGENERON PHARMACEUTICALS  : to seek U.S. OK for COVID-19 cocktail to be used fo..
RE
05:02aDiaSorin strikes $1.8 bln Luminex deal to dodge 'COVID cliff'
RE
01:21aROCHE  : Says Regeneron Antibody Cocktail Cuts Risk of Symptomatic COVID-19 Infe..
MT
01:01aPRESS RELEASE  : Phase III prevention trial showed -3-
DJ
01:01aPRESS RELEASE  : Phase III prevention trial showed -2-
DJ
01:01aROCHE  : Phase III prevention trial showed subcutaneous administration of invest..
AQ
01:01aPRESS RELEASE  : Phase III prevention trial showed subcutaneous administration o..
DJ
More news
Financials
Sales 2021 60 363 M 65 439 M 65 439 M
Net income 2021 14 752 M 15 993 M 15 993 M
Net cash 2021 4 797 M 5 201 M 5 201 M
P/E ratio 2021 17,8x
Yield 2021 3,05%
Capitalization 267 B 289 B 289 B
EV / Sales 2021 4,34x
EV / Sales 2022 4,08x
Nbr of Employees 101 465
Free-Float 82,6%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 353,44 CHF
Last Close Price 309,65 CHF
Spread / Highest target 42,4%
Spread / Average Target 14,1%
Spread / Lowest Target -6,35%
EPS Revisions
Managers and Directors
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG0.21%288 043
JOHNSON & JOHNSON2.46%424 524
PFIZER, INC.-0.57%204 161
NOVARTIS AG-3.29%197 172
MERCK & CO., INC.-6.71%193 164
ABBVIE INC.0.36%189 789